Checking for lymph node spread and tumor deposits in the posterior gastric mesentery after distal stomach cancer surgery
Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery Following D2 Lymphadenectomy Plus Complete Mesogastric Excision in Patients Who Received Distal Gastrectomy: A Prospective Observational Study
This project will check if adults having distal stomach cancer surgery (distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision) have lymph node metastases or tumor deposits in the posterior gastric mesentery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06736847 on ClinicalTrials.gov |
What this trial studies
This is an observational study of patients who undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision for gastric adenocarcinoma. Surgeons will resect the posterior gastric mesentery during the procedure and pathologists will examine the tissue for metastatic lymph nodes (including No.11p and part of No.11d) and tumor deposits. The number and distribution of positive nodes and any tumor deposits will be recorded and correlated with preoperative staging and clinical features. The study is single-center, conducted at the First Affiliated Hospital, Zhejiang University School of Medicine, and enrolls patients meeting defined inclusion and exclusion criteria.
Who should consider this trial
Good fit: Adults aged 18 to 84 with primary distal gastric adenocarcinoma staged cT2-4N0-3M0 who undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision and meet ASA I–III and other study criteria are ideal candidates.
Not a fit: Patients with very advanced or metastatic disease (cT4b/M1), prior neoadjuvant therapy, BMI over 30, prior upper abdominal surgery, total or proximal gastrectomy, or concurrent other malignancies are unlikely to benefit from the protocol findings.
Why it matters
Potential benefit: If successful, the findings could improve surgical planning and pathological staging by clarifying how often the posterior gastric mesentery harbors metastatic nodes or tumor deposits, potentially reducing recurrence from missed disease.
How similar studies have performed: Previous work, including the DCGC01 findings, suggests D2 plus CME removes more lymph nodes and may improve long-term outcomes, but detailed mapping of metastasis specifically in the posterior gastric mesentery remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged older than 18 years and younger than 85 years 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result 3. cT2-4N0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 7th Edition 4. Patients who received distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision 5. American Society of Anesthesiologists (ASA) class I, II, or III 6. Written informed consent Exclusion Criteria: 1. Negative preoperative biopsy 2. Too late tumour stage or metastasis (cT4b/M1) 3. BMI\>30 kg/m2 4. Total gastrectomy or proximal gastrectomy 5. previous neoadjuvant chemotherapy or radiotherapy 6. Previous upper abdominal surgery 7. Combined with other malignant diseases 8. Reject operation
Where this trial is running
Hangzhou, Zhejiang
- Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Tao Wang, Ph.d
- Email: 15002740874@163.com
- Phone: +86-197-068-25286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.